Apieron inhales funds for asthma monitor
Apieron, maker of a device that monitors asthmatic conditions, has brought in an undisclosed sum in a fourth round of financing from existing investors Alliance Technology Ventures, Canaan Partners, Draper Fisher Jurvetson and Onset Ventures. Based in Menlo Park, Calif., the company says its lead product, which measures lung inflammation, has already earned requisite approval. It says the new funds will go toward marketing and further product development.
In 2003, Apieron brought in $4.6 million from… Continue Reading
Apieron seeks $25M under new leadership
Apieron Inc. plans to score $25 million in its currently open fourth-round of funding to advance development and build up sales of an asthma monitoring device.
This round is the first of Holly McGarraugh’s brand new tenure as president and chief executive officer. She joined the Menlo Park, Calif.-based company in January as vice president for marketing. While the company is still busy hammering out term sheets with venture capital firms, McGarraugh says the round should… Continue Reading
Life sciences briefing: Monday, Nov. 12, 2007
(UPDATED: See below.)
Featured companies: Anaptys Biosciences, Arterial Remodeling Technologies, Cambria Biosciences, CaseNet, ChemoCentryx, Ensemble Discovery, MediQuest, Piedmont Pharmaceuticals, Raven Biotechnologies, Sensys Medical, Verus Pharmaceuticals, Xanodyne Pharmaceuticals
UPDATED: Expanded items on Anaptys, Arterial Remodeling, Raven Biotech, Sensys and MediQuest. Moved ChemoCentryx and Xanodyne to a separate item.
Antibody-drug maker Raven Biotech merges with VaxGen — Raven Biotechnologies, a South San Francisco biotech developing antibody drugs, is merging with the troubled, publicly held vaccine maker VaxGen. The confusingly worded release is here.
Although… Continue Reading